Darzalex combination wins NICE nod for newly-diagnosed multiple myeloma

22 September 2023

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) alongside lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use in England and Wales.

The Janssen therapy is now recommended within a National Health Service (NHS) setting for the treatment of adults with newly-diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable.

"We have worked diligently with NICE and NHS England over a number of years to navigate system challenges and achieve this outcome for patients"Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: “DLd is a game changer that will make a tremendous difference to patients’ quality of life and help to close the gap in survival between people who are eligible for a stem cell transplant and those who are not.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK